Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Treasury Shares (2016 - 2025)

Guided Therapeutics' Treasury Shares history spans 16 years, with the latest figure at $132000.0 for Q3 2025.

  • For Q3 2025, Treasury Shares changed 0.0% year-over-year to $132000.0; the TTM value through Sep 2025 reached $132000.0, changed 0.0%, while the annual FY2024 figure was $132000.0, 0.0% changed from the prior year.
  • Treasury Shares for Q3 2024 was $678000.0 at Guided Therapeutics, roughly flat from $678000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $678000.0 in Q2 2021 and bottomed at $153000.0 in Q4 2021.
  • The 4-year median for Treasury Shares is $678000.0 (2021), against an average of $640500.0.
  • The largest YoY upside for Treasury Shares was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • A 5-year view of Treasury Shares shows it stood at $132000.0 in 2021, then changed by 0.0% to $132000.0 in 2022, then changed by 0.0% to $132000.0 in 2023, then changed by 0.0% to $132000.0 in 2024, then changed by 0.0% to $132000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Treasury Shares are $132000.0 (Q3 2025), $132000.0 (Q2 2025), and $132000.0 (Q1 2025).